Form 4: Aspira Women's Health CEO Awarded 25,000 Restricted Stock Units
SEC Form 4 Filing
Aspira Women's Health CEO, Nicole Sandford, received 25,000 restricted stock units that will vest on December 31, 2024, according to a Form 4 filing.
Summary
- Nicole Sandford, CEO of Aspira Women's Health Inc., was granted 25,000 restricted stock units on October 28, 2024.
- These restricted stock units represent the contingent right to receive one share of Aspira Women's Health's common stock per unit.
- The award will vest 100% on December 31, 2024, contingent upon Sandford's continued service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning management interests with shareholders. The vesting schedule provides a clear incentive for continued service.
Positives
- The granting of restricted stock units to the CEO aligns her interests with those of the shareholders, incentivizing her to drive company performance.
Risks
- The vesting of the restricted stock units is contingent upon the CEO's continued service, creating a potential risk if she were to leave the company before the vesting date.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.
Industry Context
Granting stock options and restricted stock units to executives is a common practice in the healthcare industry to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Executive compensation packages, including restricted stock units, are common in publicly traded companies, particularly in the healthcare sector.
- The size and vesting schedule of the award would need to be compared to similar companies in the diagnostics and women's health space to determine if it is in line with industry standards.
Stakeholder Impact
- Shareholders may view the grant of restricted stock units positively, as it incentivizes the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| September 1, 2024 | Effective date of amended contract related to the restricted stock unit award. |
| October 28, 2024 | Date of transaction: Grant of restricted stock units. |
| December 31, 2024 | Vesting date for the restricted stock units. |
Keywords
restricted stock units, Aspira Women's Health, CEO, Nicole Sandford, equity compensation, Form 4, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.